NCT06410248View on ClinicalTrials.gov

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

May 12, 2029

Study Completion Date

May 12, 2030

Conditions
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 Glioma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Resection

Undergo surgical resection

DRUG

Temozolomide

Given PO

DRUG

Triapine

Given PO

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

BrainUp Inc
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

BrainUp Inc

UNKNOWN

lead

Northwestern University

OTHER

NCT06410248 - Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter